Swarup Gupta

The global biosimilars space is expected to generate $24 billion in 2019. These three pharma companies worth investing in are present in the biosimilar arena or quickly increasing their presence.

Though the economic situation in Japan may look slightly grim at the moment, Prime Minister Shinzo Abe's policies could well bear fruit in the long run.This is why some Japanese stocks are extremely good long term options.